Breaking News Instant updates and real-time market news.

CLLS

Cellectis

$17.62

0.22 (1.26%)

, RIGL

Rigel Pharmaceuticals

$2.69

-0.01 (-0.37%)

07:50
11/30/16
11/30
07:50
11/30/16
07:50

Piper Jaffray to hold a conference

28th Annual Piper Jaffray Healthcare Conference is being held in New York on November 29-30 with webcasted company presentations to begin on November 30 at 8 am; not all company presentations may be webcasted. Webcast Link

CLLS

Cellectis

$17.62

0.22 (1.26%)

RIGL

Rigel Pharmaceuticals

$2.69

-0.01 (-0.37%)

NVO

Novo Nordisk

$32.72

0.18 (0.55%)

SPNC

Spectranetics

$22.50

-0.1 (-0.44%)

INSY

Insys Therapeutics

$12.79

0.17 (1.35%)

SNDX

Syndax

$10.21

0.27 (2.72%)

TRHC

Tabula Rasa HealthCare

$13.86

0.61 (4.60%)

VASC

Vascular Solutions

$53.75

-0.45 (-0.83%)

MNK

Mallinckrodt

$52.42

-5.25 (-9.10%)

GTXI

GTx

$0.82

0.035 (4.49%)

TROV

Trovagene

ANTH

Anthera

$1.76

-0.01 (-0.56%)

CBAY

CymaBay

$1.89

-0.07 (-3.57%)

LBIO

Lion Biotechnologies

$6.80

-0.15 (-2.16%)

RVNC

Revance

$17.50

-0.1 (-0.57%)

COLL

Collegium Pharmaceutical

$16.31

-0.05 (-0.31%)

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 04

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

CLLS Cellectis
$17.62

0.22 (1.26%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
04/05/16
LTCO
04/05/16
INITIATION
Target $45
LTCO
Buy
Cellectis initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Cellectis with a Buy rating and $45 price target.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
10/27/16
LTCO
10/27/16
NO CHANGE
Target $45
LTCO
Buy
Cellectis recent selloff unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li says the recent pullback in shares of Cellectis is unwarranted. The UCART19 Phase 1 trial is dosing patients on schedule, which is a positive sign for the outcome readout of the trial, Li tells investors in a research note. The analyst recommends buying the shares on the pullback and keeps a Buy rating on the name with a $45 price target.
RIGL Rigel Pharmaceuticals
$2.69

-0.01 (-0.37%)

10/20/16
JPMS
10/20/16
NO CHANGE
JPMS
Overweight
Rigel has 20%-40% near-term downside, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Rigel Pharmaceuticals now have a regulatory uncertainty overhang after the company's second phase 3 trial of fostamatinib in immune thrombocytopenic missed statistical significance on its primary endpoint.There could ultimately be a registration path forward with combined phase 3 dataset, however, Rama tells investors in a research note. Nonetheless, the analyst sees the potential for 20%-40% share downside in the near-term. Rama has an Overweight rating on Rigel. The stock is down 34% to $2.11 in pre-market trading.
09/16/16
JEFF
09/16/16
NO CHANGE
Target $9
JEFF
Buy
Jefferies views Rigel restructuring positively, ups target to $9
Jefferies analyst Eun Yang views Rigel Pharmaceuticals' restructuring, which prioritizes fostamatinib commercialization while reducing research workforce, as a positive. The analyst notes the move will have no impact on the company's early programs. She raised her price target for Rigel shares to $9 from $8.50 and keeps a Buy rating on the name. Rigel closed yesterday up 4c to $3.45. The next major catalyst for the stock will be second Phase 3 data for fostamatinib in Immune Thrombocytopenic Purpura in October or November, Yang tells investors in a research note. She expects additional indications opportunities to drive "meaningful share price appreciation."
08/31/16
BMOC
08/31/16
NO CHANGE
BMOC
Rigel Pharmaceuticals price target raised to $6 from $4 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Rigel following positive results from the first of two Phase III trials for fostamatinib in chronic ITP. The analyst says that the significant 18% response rate versus placebo supports FDA approval and his estimate of $742M of peak sales in ITP. The analyst thinks that the chances of the drug showing positive results in an upcoming Phase II trial in AIHA have increased, since the diseases have the same mechanism. He keeps an Outperform rating on the shares.
10/20/16
PIPR
10/20/16
NO CHANGE
PIPR
Overweight
Rigel Pharmaceuticals risk/reward remains favorable, says Piper Jaffray
With the stock down nearly 35% in pre-market trading, Piper Jaffray analyst Joshua Schimmer believes the risk/reward on shares of Rigel Pharmaceuticals remains favorable. The company on the conference call did an "excellent job" explaining the failed second Phase III results for fostamatinib in immune thrombocytopenic, Schimmer tells investors in a research note. He believes the drug has a "clear therapeutic benefit" and reiterates an Overweight rating on the stock with an $11 price target.
NVO Novo Nordisk
$32.72

0.18 (0.55%)

09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Outperform
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
10/31/16
SBSH
10/31/16
DOWNGRADE
SBSH
Neutral
Novo Nordisk downgraded to Neutral from Buy at Citi
Citi analyst Peter Verdult downgraded Novo Nordisk to Neutral citing the ongoing net pricing declines across the company's diabetes portfolio as well as expectations for margin erosion at Biopharmaceuticals due to NovoSeven/Norditropin pressures. The analyst cut his price target for the shares to DKK 260 from DKK 400.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Novo Nordisk initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Novo Nordisk with a Neutral rating and DKK 320 price target.
10/28/16
BOFA
10/28/16
DOWNGRADE
BOFA
Underperform
Novo Nordisk downgraded to Underperform from Neutral at BofA/Merrill
SPNC Spectranetics
$22.50

-0.1 (-0.44%)

08/09/16
NEED
08/09/16
DOWNGRADE
Target $27
NEED
Buy
Spectranetics downgraded to Buy from Strong Buy at Needham
Needham analyst Mike Matson downgraded Spectranetics to Buy from Strong Buy on valuation. Nonetheless, the analyst is more positive about its Stellarex's ability to take share in the drug-coated balloon market and the company's ability to sustain strong growth in the base Vascular Intervention business after meeting with Spectranetics' CEO Scott Drake and COO Shar Matin. The analyst has a $27 price target on the shares.
10/21/16
NEED
10/21/16
NO CHANGE
Target $32
NEED
Buy
Spectranetics price target raised to $32 from $27 at Needham
Needham analyst Mike Matson raised his price target for Spectranetics to $32 from $27 ahead of results from the company's ILLUMENATE Pivotal trial, which should be presented next month. With earlier data showing "very good" results, the analyst expects the pivotal data to be similar. Nonetheless, Matson thinks Spectranetics's shares may be range-bound until the Stellarex approval drives a significant acceleration in revenue growth next year. The analyst reiterates a Buy rating on the stock.
07/07/16
ADAM
07/07/16
NO CHANGE
ADAM
Buy
Canaccord calls Spectranetics, Avinger buys after reimbursement announcement
Canaccord analyst Jason Mills reiterated the firm's Buy ratings on Spectranetics (SPNC ) and Avinger (AVGR) after CMS announced proposed 2017 policy and payment changes to the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System, noting that the proposal does not include any material changes to outpatient hospital-based peripheral atherectomy payments for next year. The proposed rule for the Physician Fee Schedule will be "the final piece of the outpatient reimbursement puzzle," the analyst tells investors.
08/03/16
UBSW
08/03/16
UPGRADE
Target $30
UBSW
Buy
Spectranetics upgraded to Buy from Sell at UBS
UBS analyst Matt Miksic double upgraded Spectranetics to Buy from Sell and tripled his price target for the shares to $30 from $10. The company's Q2 results showed stabilization of the core Vascular Intervention businesses for peripheral and coronary intervention, clearing the way for the Stellarex drug-coated balloon platform to take over as the central value driver for the stock, Miksic tells investors in a post-earnings research note. The analyst projects 26% market share for Stellarex in 2020 on "strong clinical data."
INSY Insys Therapeutics
$12.79

0.17 (1.35%)

08/04/16
JEFF
08/04/16
NO CHANGE
Target $22
JEFF
Buy
Insys Therapeutics price target raised to $22 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
08/26/16
JANY
08/26/16
NO CHANGE
Target $22
JANY
Buy
Illinois 'highly unlikely' to be able to bar Insys sales, says Janney Capital
Janney Capital analyst Ken Trbovich said he thinks it is "highly unlikely" that Illinois' Attorney General will succeed with her proposal to ban Insys Therapeutics from doing business in the state, pointing to the fact that a similar attempt by Massachusetts in 2014 was struck down by a federal judge. This story, and the trading in its wake yesterday, clearly indicate Insys has headline risks from ongoing state and federal investigations, acknowledged Trbovich, but he thinks the risk will be eliminated by a settlement for an amount the company can manage from its existing cash. The analyst keeps a Buy rating and $22 fair value estimate on Insys shares, which fell about 4.6% yesterday to close at $14.98.
04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/16
JANY
07/05/16
NO CHANGE
Target $22
JANY
Buy
Insys approval of Syndros may trigger short squeeze, says Janney Capital
Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.
SNDX Syndax
$10.21

0.27 (2.72%)

03/31/16
OPCO
03/31/16
INITIATION
OPCO
Outperform
Syndax initiated with an Outperform at Oppenheimer
Target $24.
10/07/16
GUGG
10/07/16
INITIATION
Target $29
GUGG
Buy
Syndax initiated with a Buy at Guggenheim
Guggenheim analyst Charles Butler initiated Syndax with a Buy and a $29 price target.
03/28/16
03/28/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Berkshire Hathaway (BRK.A) initiated with a Buy at UBS by analyst Brian Meredith, who said the current and uncertain economic and market environment "plays into the hands" of the company. 2. Syndax (SNDX) initiated with an Outperform and Overweight at JMP Securities and Morgan Stanley, respectively. 3. ONEOK (OKE) initiated with a Sector Perform at RBC Capital. 4. Phillips 66 (PSX) initiated with a Market Perform at Cowen. 5. Western Digital (WDC) initiated with a Buy at Summit Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/16
JMPS
03/28/16
INITIATION
Target $28
JMPS
Outperform
Syndax initiated with an Outperform at JMP Securities
Target $28.
TRHC Tabula Rasa HealthCare
$13.86

0.61 (4.60%)

10/24/16
UBSW
10/24/16
INITIATION
Target $18
UBSW
Buy
Tabula Rasa HealthCare initiated with a Buy at UBS
UBS analyst Michael Cherny started Tabula Rasa HealthCare with a Buy rating and $18 price target.
10/24/16
BARD
10/24/16
INITIATION
Target $17
BARD
Outperform
Tabula Rasa HealthCare initiated with an Outperform at Baird
Baird analyst Matthew Gillmor started Tabula Rasa HealthCare with an Outperform rating and $17 price target.
10/24/16
10/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Avis Budget (CAR) initiated with a Neutral at Goldman. 2. Fulgent Genetics (FLGT) initiated with an Overweight at Piper Jaffray, a Buy at BTIG, and an Outperform at Credit Suisse. 3. MedEquities (MRT) Realty Trust initiated with a Neutral at Citi, a Neutral at JPMorgan, an Outperform at JMP Securities, an Outperform at RBC Capital, an Outperform at FBR Capital, and an Outperform at Raymond James. 4. Tabula Rasa HealthCare (TRHC) initiated with an Overweight at Piper Jaffray, a Buy at Stifel, an Outperform at Baird, a Buy at UBS, and an Outperform at Wells Fargo. 5. Agios Pharmaceuticals (AGIO) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/16
WELS
10/24/16
INITIATION
WELS
Outperform
Tabula Rasa HealthCare initiated with an Outperform at Wells Fargo
Wells Fargo analyst Peter Costa started Tabula Rasa HealthCare with an Outperform rating and $14-$16 price target range.
VASC Vascular Solutions
$53.75

-0.45 (-0.83%)

11/15/16
NEED
11/15/16
NO CHANGE
Target $58
NEED
Buy
Vascular Solutions can exceed consensus estimates in 2017, says Needham
Needham analyst Mike Matson says he is "most positive" on Vascular Solutions given increased confidence that the company can exceed consensus estimates in 2017, with upside driven by new product launches and M&A. The analyst notes that Vascular Solutions plans 12 new product launches in 2017, which is almost double the 6-7 launched in 2016. Furthermore, Matson thinks the company will announce several tuck-in deals during 2017, and expects these to be accretive to its EPS. He reiterates a Buy rating and $58 price target on the shares.
10/06/16
NEED
10/06/16
INITIATION
Target $58
NEED
Buy
Vascular Solutions initiated with a Buy at Needham
Needham analyst Mike Matson initiated Vascular Solutions with a Buy and a $58 price target.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $51
ADAM
Buy
Vascular Solutions weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the weakness in Vascular Solutions following the announcement of a product recall is a buying opportunity. The analyst sees the recall as a non-event and expects the product to resume shipping within a few weeks and be back to a level of full stocking at customer sites within a quarter. Mills reiterated his Buy rating and $51 price target on Vascular Solutions shares.
10/25/16
ADAM
10/25/16
NO CHANGE
Target $53
ADAM
Buy
Plenty of reasons to remain buyers of Vascular Solutions, says Canaccord
Canaccord analyst Jason Mills said he sees plenty of reasons to remain buyers of Vascular Solutions following its Q3 results. The analyst said he sees an auspicious setup for the stock in 2017 citing its pipeline, operating guidance, strong cash flow, and new products. Mills reiterated his Buy rating and raised his price target to $53 from $51 on Vascular Solutions shares.
MNK Mallinckrodt
$52.42

-5.25 (-9.10%)

11/21/16
UBSW
11/21/16
NO CHANGE
Target $92
UBSW
Buy
Mallinckrodt weakness does not make sense, says UBS
UBS analyst Marc Goodman attended Mallinckrodt investors meetings and came away believing investors misunderstand the company story. The analyst said the company's Acthar drug, which has come under fire, has little relevance to the overall story. Goodman said the company has focused on enhancing clinical and health-economics data to help support better coverage and it is working. He said its emerging pipeline is under-appreciated. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
11/17/16
RAJA
11/17/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform at Raymond James
Raymond James initiated Mallinckrodt with an Outperform and a $72 price target.
11/30/16
LEER
11/30/16
NO CHANGE
Target $70
LEER
Outperform
Mallinckrodt price target lowered to $70 from $92 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Mallinckrodt to $70 from $92 following quarterly results due to a lack of near-term catalysts. The analyst reiterates an Outperform rating on the shares.
11/18/16
RAJA
11/18/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform and $72 price target at Raymond James
Raymond James analyst Elliot WIlbur initiated Mallinckrodt with an Outperform and a $72 price target saying negative sector sentiment combined with further allegations from short sellers have created a compelling entry point. Wilbur believes Mallinckrodt provides one of the most sustainable top and bottom line growth trajectories in specialty pharmaceuticals and notes Achar has only a 3% penetration rate of the total addressable market, giving it a long runway of growth.
GTXI GTx
$0.82

0.035 (4.49%)

TROV Trovagene

08/08/16
CANT
08/08/16
UPGRADE
CANT
Buy
Trovagene upgraded to Buy from Hold at Cantor
08/08/16
CANT
08/08/16
UPGRADE
Target $7
CANT
Buy
Trovagene upgraded to Buy with $7 target at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier upgraded Trovagene to Buy from Hold citing the company's accelerating clinical business. In Q2, the company increased the number of physicians on the platform to approximately 700 physicians from 550 in Q1, Brokmeier tells investors in a research note. He points out that Trovagene is also targeting new biopharma collaborations. The analyst raised his price target for the shares to $7 from $5.
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees tax holiday as potential catalyst for Medical Diagnostics space
A repatriation tax holiday represents a potential catalyst for the Medical Diagnostics space, Piper Jaffray analyst William Quirk tells investors in a research note. Quirk notes that Becton Dickinson (BDX), Illumina (ILMN) and PerkinElmer (PKI) disclose cash held overseas and that all have highlighted share repurchases and acquisitions as priorities. He believes a repatriation event could be a catalyst for small lab deals. Acquisition targets include CareDx (CDNA), Genomic Health (GHDX), Oxford Immunotec (OXFD), Trovagene (TROV) and Veracyte (VCYT), Quirk tells investors.
09/30/16
CANT
09/30/16
NO CHANGE
CANT
Trovagene outlook has improved, says Cantor
After meeting with Trovagene's management, Cantor analyst Bryan Brokmeier is more upbeat on the stock. He says that the company's new strategy :"significantly reduces" its cash needs, provides it with multiple potential positive catalysts and reduces its competition. The analyst keeps an $8 price target and Buy rating on the shares.
ANTH Anthera
$1.76

-0.01 (-0.56%)

07/08/16
HCWC
07/08/16
INITIATION
Target $10
HCWC
Buy
Anthera initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Anthera with a Buy and $10 price target saying shares are attractive ahead of the Sollpura topline data expected by year-end.
03/29/16
SBSH
03/29/16
NO CHANGE
SBSH
Citi lays out potential targets for next biotech M&A wave
Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).
07/08/16
07/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Neutral at Wedbush. 2. PayPal (PYPL) initiated with an Overweight at Stephens. 3. GrubHub (GRUB) initiated with an Outperform at Wedbush. 4. Anthera (ANTH) initiated with a Buy at H.C. Wainwright. 5. 58.com (WUBA) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/16
SBSH
11/11/16
NO CHANGE
Target $6
SBSH
Buy
Anthera price target lowered to $6 from $10 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Anthera Pharmaceuticals to $6 after the company announced that its Phase III trial failed to meet the primary endpoint in systemic lupus erythematosus. The result is not a "huge surprise" as the program always carried high risk, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on the shares, citing significantly higher conviction for Sollpura. He recommends buying on yesterday's weakness.
CBAY CymaBay
$1.89

-0.07 (-3.57%)

06/01/16
HCWC
06/01/16
DOWNGRADE
Target $2.25
HCWC
Neutral
CymaBay downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded CymaBay Therapeutics to Neutral saying that while the primary biliary cholangitis study stopped early for strong efficacy, increases in transaminases renders the overall result uncertain. The analyst has a $2.25 price target for the shares.
11/16/16
PIPR
11/16/16
NO CHANGE
Target $5
PIPR
Overweight
CymaBay price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for CymaBay Therapeutics to $5 after the company gave two oral presentations on MBX-8025. In the Phase II study, both 50mg and 200mg MBX-8025 significantly reduced Alkaline Phosphatase, but three patients had dose-dependent transaminase elevations, Tenthoff tells investors in a research note. To analyst sees increased value for MBX-8025 and reiterates an Overweight rating on CymaBay.
07/01/16
ROTH
07/01/16
INITIATION
Target $4
ROTH
Buy
CymaBay coverage resumed with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of CymaBay with a Buy rating and $4 price target.
LBIO Lion Biotechnologies
$6.80

-0.15 (-2.16%)

06/10/16
FBRC
06/10/16
NO CHANGE
Target $20
FBRC
Outperform
FBR adds Corium to Alpha Generator list, removes Lion
FBR Capital analyst Ed White added Corium (CORI) to his firm's Alpha Generator list while removing Lion Biotechnologies (LBIO). Corium is being underestimated by the Street as its management has a well-strategized plan to bring Corplex donepezil and Corplex memantine to market, White contends. He has an Outperform rating on the shares with a $20 price target. The analyst lowered his price target for Lion to $18 following the closing of its private financing. He reiterates an Outperform rating on the shares, however, saying it remains one of his top picks.
07/08/16
ROTH
07/08/16
NO CHANGE
Target $15
ROTH
Buy
Lion T cell therapies not that similar to Juno candidate, says Roth Capital
Roth Capital analyst Joseph Pantginis says yesterday's announcement that the Phase II study of Juno Therapeutic's (JUNO) lead candidate, JCR015, was suspended over the deaths of two patients had ripple effects on the space. However, the analyst points out that while both JCR015 and Lion Biotechnologies' (LBIO) LN-144 are T cell therapies with similar preconditioning regimens, the similarities end there. Lion's T cell therapies have not demonstrated characteristic safety profiles of concern, Pantginis tells investors in a research note. He reiterates a Buy rating and $15 on Lion's shares.
RVNC Revance
$17.50

-0.1 (-0.57%)

06/14/16
RHCO
06/14/16
NO CHANGE
RHCO
Revance price target lowered to $22 from $46 at SunTrust
SunTrust cut its price target on Revance after the company discontinued its RT001 topical development program for lateral canthal lines and excessive sweating due to negative Ph-3 REALISE-1 data. The firm notes that the company is still working on a number of additional treatments. It keeps a Buy rating on the shares.
11/29/16
AGIS
11/29/16
INITIATION
Target $28
AGIS
Buy
Revance initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Revance with a Buy and a $28 price target.
06/14/16
COWN
06/14/16
NO CHANGE
COWN
Outperform
Revance shares defended at Cowen
06/14/16
COWN
06/14/16
NO CHANGE
Target $55
COWN
Outperform
Revance key value driver remains RT002, says Cowen
Cowen analyst Ken Cacciatore said he shares in the disappointment that Revance's RT001 program is not moving forward, but adds that he believes expectations were low and that investor focus had already shifted, and remains fixed, on the injectable RT002 program, which is the company's key value driver. Cacciatore, who still thinks that RT002 could become a $1B+ product, maintains an Outperform rating and $55 price target on Revance shares, which are down 22% to $14.30 in morning trading.
COLL Collegium Pharmaceutical
$16.31

-0.05 (-0.31%)

09/13/16
GABE
09/13/16
INITIATION
Target $23
GABE
Buy
Collegium Pharmaceutical initiated with a Buy at Gabelli
Gabelli initiated Collgium with a Buy and a $23 price target.
06/23/16
PIPR
06/23/16
NO CHANGE
Target $27
PIPR
Overweight
Piper says doctor survey reinforces confidence in uptake of Collegium's Xtampza
After surveying 32 physicians with significant experience prescribing extended-release opioids, Piper Jaffray analyst David Amsellem said the responses reinforced his view that Collegium's Xtampza ER will likely gain significant traction. The analyst reiterates an Overweight rating on Collegium and bumped up his price target on shares to $27 from $26 to reflect new Xtampza ER estimates and inclusion of recently acquired Onsolis.
05/11/16
JANY
05/11/16
NO CHANGE
Target $25
JANY
Buy
Collegium data on advantages of Xtampza overlooked, says Janney Capital
Janney Capital analyst Ken Trbovich said "key data" on the advantages of Collegium Pharmaceutical's Xtampza relative to Oxycontin went overlooked by the market last week, but should be featured at the company's upcoming investor day and will likely lead to an improved label for the drug in 2017. The firm reiterates its Buy rating and $25 fair value estimate on Collegium shares.
03/15/16
JANY
03/15/16
INITIATION
Target $25
JANY
Buy
Collegium Pharmaceutical initiated with a Buy at Janney Capital (last night)
Janney Capital initiated coverage of Collegium Pharmaceutical last night with a Buy rating and $25 fair value estimate.

TODAY'S FREE FLY STORIES

AAPL

Apple

$151.89

-1.5 (-0.98%)

05:55
09/25/17
09/25
05:55
09/25/17
05:55
Recommendations
Apple analyst commentary  »

Citi lowers Apple Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

05:49
09/25/17
09/25
05:49
09/25/17
05:49
Hot Stocks
Amazon Web Services announces opening of data centers in Middle East by 2019 »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

CVE

Cenovus Energy

$10.28

0.18 (1.78%)

05:46
09/25/17
09/25
05:46
09/25/17
05:46
Hot Stocks
Cenovus Energy reaches agreement to sell Suffield assets for $512M »

Cenovus Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JHG

Janus Henderson Group

$33.96

0.42 (1.25%)

05:39
09/25/17
09/25
05:39
09/25/17
05:39
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMES

Emerge Energy

$9.17

0.44 (5.04%)

05:36
09/25/17
09/25
05:36
09/25/17
05:36
Initiation
Emerge Energy initiated  »

Emerge Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.10

0.3 (3.06%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Hot Stocks
Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective »

Exelixis (EXEL) announced…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

VFC

VF Corp.

$62.20

0.35 (0.57%)

, UAA

Under Armour

$16.41

-0.08 (-0.49%)

05:31
09/25/17
09/25
05:31
09/25/17
05:31
Downgrade
VF Corp., Under Armour, Under Armour rating change  »

VF Corp. downgraded to…

VFC

VF Corp.

$62.20

0.35 (0.57%)

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

UAA

Under Armour

$16.41

-0.08 (-0.49%)

, UA

Under Armour

$15.04

-0.09 (-0.59%)

05:28
09/25/17
09/25
05:28
09/25/17
05:28
Upgrade
Under Armour, Under Armour, VF Corp. rating change  »

Under Armour upgraded to…

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

VFC

VF Corp.

$62.20

0.35 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$13.70

-0.07 (-0.51%)

05:24
09/25/17
09/25
05:24
09/25/17
05:24
Recommendations
Snap analyst commentary  »

Snap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$60.10

-9.4 (-13.53%)

05:20
09/25/17
09/25
05:20
09/25/17
05:20
Upgrade
Compass Minerals rating change  »

Compass Minerals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

COR

CoreSite Realty

$108.49

-1.86 (-1.69%)

05:18
09/25/17
09/25
05:18
09/25/17
05:18
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ROST

Ross Stores

$60.89

-0.02 (-0.03%)

05:17
09/25/17
09/25
05:17
09/25/17
05:17
Upgrade
Ross Stores rating change  »

Ross Stores upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFC

Corporate Office Properties

$32.53

-0.13 (-0.40%)

05:11
09/25/17
09/25
05:11
09/25/17
05:11
Upgrade
Corporate Office Properties rating change  »

Corporate Office…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMRF

ABN Amro

05:08
09/25/17
09/25
05:08
09/25/17
05:08
Upgrade
ABN Amro rating change  »

ABN Amro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.42

0.32 (0.82%)

05:05
09/25/17
09/25
05:05
09/25/17
05:05
Upgrade
General Motors rating change  »

General Motors upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$9.12

-0.1 (-1.08%)

04:59
09/25/17
09/25
04:59
09/25/17
04:59
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$36.57

0.45 (1.25%)

04:56
09/25/17
09/25
04:56
09/25/17
04:56
Downgrade
Butterfield rating change  »

Butterfield downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$2.68

-18.925 (-87.62%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

HSC

Harsco

$19.75

0.35 (1.80%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

IIVI

II-VI

$40.40

0.45 (1.13%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

AMCX

AMC Networks

$59.08

0.14 (0.24%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
AMC Networks management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

September Dallas Fed Mfg…

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.